Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 5/20 | 0.47 |
| ▸ | MAP2K7 | O14733 | 5/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912985 | 0.85 | KDR (0.59) | KDRTNNI3KBRAFRAF1MAP2K7 | |
| SCHEMBL2780055 | 0.80 | ALDH1A1 (0.50) | KDRALDH1A1BRAFTRPV1 | |
| SCHEMBL17164822 | 0.76 | NPC1 (0.61) | KDRALDH1A1BRAF | |
| SCHEMBL22592313 | 0.74 | KDR (0.67) | KDRTNNI3KBRAFRAF1MAP2K7 | |
| SCHEMBL2778530 | 0.74 | KDR (0.47) | KDRTNNI3KBRAFRAF1MAP2K7 | |
| SCHEMBL3872895 | 0.73 | ALDH1A1 (0.47) | KDRALDH1A1BRAFTRPV1 | |
| SCHEMBL2434197 | 0.73 | KDR (0.70) | KDRTNNI3KBRAFRAF1MAP2K7 | |
| SCHEMBL3177337 | 0.73 | KDR (0.58) | KDRTNNI3KBRAFRAF1MAP2K7 | |
| SCHEMBL31118855 | 0.72 | ALDH1A1 (0.50) | KDRALDH1A1BRAFTRPV1 | |
| SCHEMBL5553606 | 0.72 | ALDH1A1 (0.61) | KDRALDH1A1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | KDR 479/4885TNNI3K 270/4885ALDH1A1 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.